| Summary: | 碩士 === 國立中山大學 === 生物醫學研究所 === 102 === Monoclonal antibody has become clinical medicine of a variety of disease widely. According to the statistics of drug use, monoclonal antibody therapies apply to cancer, autoimmune diseases, inflammation and many infectious diseases, etc. And through the market statistics point out the sales of monoclonal antibodies is up to $ 43 billion in the market of global antibody drug in 2010. Moreover single sales target several strains of antibodies will create more than $ 1 billion sales, including Colorectal cancer drug, ERBITUX® (Cetuximab)、breast cancer drug HERCEPTIN® (Trastuzumab)、rheumatoid arthritis drug REMICADE® (Infliximab) and HUMIRA® (Adalimumab) , etc. Over the past 20 years, monoclonal antibody therapy in cancer medicine has many successful examples, and become a staple of drugs in the medical profession base on the binding-specificity between antibody and antigen in order to block the cell pathway for inhibiting tumor growth or other disease. Monoclonal antibody therapy on medical breakthroughs and success promote many studies are still committed to finding out the diseases targeted therapy can be used as a sign of disease in order to benefit more patients, and more clinical treatment is combination of antibody with traditional chemotherapy drugs, radiation therapy, or other small molecule drugs for more effective inhibition of cancer cell proliferation to enhance the therapeutic efficacy. Thus the development of innovative monoclonal antibody has the full potential in future.
|
|---|
